Digital Paid Media Specialist - Digital Marketing & Revenue Acquisition
About the job
- At least 3 years of hands-on experience managing PPC campaigns.
- Strong expertise in Google Ads, Meta Ads, and Microsoft Ads.
- Experience with Google Analytics and Google Tag Manager.
- Experience managing large budgets and multi-country campaigns.
- Experience with landing page tools such as HubSpot or similar.
- High level of English in written and spoken communication.
- Bachelor's degree in Digital Marketing or a related field, or equivalent experience.
- Eligibility to work within the European Union.
- Set up, manage, and optimize campaigns across Google Ads, Microsoft Ads, Meta Ads, LinkedIn, and programmatic platforms.
- Monitor daily performance of EMEA PPC campaigns and implement optimizations.
- Lead Google Shopping campaigns, including optimization, expansion, and feed management.
- Conduct regular account audits to identify growth opportunities.
- Analyze campaign data to generate insights and actionable recommendations.
- Ensure campaign strategies align with broader marketing objectives and brand guidelines.
- Create ad copy and assets using artificial intelligence tools where applicable.
- Collaborate with the Analytics team to ensure accurate tracking and measurement.
- Report on key performance indicators including cost per click, click-through rate, return on ad spend, cost per acquisition, and conversion rate.
- Manage budgets to maximize return on investment and achieve targets.
- Stay current with PPC best practices, platform updates, and emerging trends.
- Support automation initiatives and artificial-intelligence-driven optimization.
- Contribute to search engine optimization and broader digital strategy discussions.
- Assist in building and optimizing HubSpot landing pages, including A/B testing and conversion rate optimization.
- Travel less than 10%.
- Experience managing PPC campaigns across the EMEA or international scope.
- Additional European languages.
- Google Ads certification.
- Agency experience.
About the company
Henry Schein is a global supplier of healthcare products and services. It operates in two segments: healthcare distribution, which provides dental and medical consumables, equipment, and laboratory products to dentists, physicians, and veterinarians; and technology and value-added services, which offers practice management software, e-commerce solutions, and financial services. The company works by supplying healthcare professionals with a broad range of products and by offering software, online tools, and financing options to run their practices more efficiently. Compared with competitors, Henry Schein combines a wide product catalog with software and financial services, creating a one-stop platform for practice needs across more than 30 countries, with a strong focus on North America. Its goal is to be a trusted partner for healthcare professionals by supporting their day-to-day operations and growth through integrated distribution, technology, and financing solutions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Town of Huntington, New York
Founded
1932
Get referred to Henry Schein
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales reached $3.5 billion, and management raised full-year guidance.
- Dentrix Ascend installs tripled since January 2025, with June's record new-customer month.
- The $1.25 billion credit facility extends to September 19, 2031, funding buybacks and acquisitions.
What critics are saying
- July 30, 2026 leadership restructuring exits three executives on October 30, 2026.
- Henry Schein One faces Maryland and Utah lawsuits with filings continuing September 2026.
- Q2 2026 restructuring expense hit $29 million; repeated charges pressure GAAP earnings.
What makes Henry Schein unique
- Henry Schein One serves 90% of top 50 DSOs with recurring, high-margin software.
- One Schein bundles distribution, exclusive brands like Curodont, and practice software.
- Camlog, Biotech Dental, and Edge strengthen proprietary pricing against commodity distributors.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Paid Vacation
Paid Parental Leave
Short Term Disability
Health Savings Account/Flexible Spending Account
Education Benefits
Growth & Insights and Company News
6 month growth
7%1 year growth
7%2 year growth
7%Henry Schein Cares, the corporate citizenship programme of Henry Schein, Inc., is celebrating its 25th anniversary. Since its launch in 2001, the programme has contributed more than $285 million in cash and donated products whilst collaborating with over 5,000 charitable partners worldwide. The programme operates through five pillars: catalysing healthcare access, advancing policies and solutions, relationship building, empowering Team Schein, and sustaining the planet. Key initiatives include supporting the American Dental Association Foundation's Give Kids A Smile programme, which has helped more than 10.2 million underserved children receive oral health services since 2003. Henry Schein celebrated the milestone during UN General Assembly Week in New York City. The company is advancing towards its Net Zero 2050 goal and aims to source 100% renewable energy by 2030.
Henry Schein has amended and restated its revolving credit agreement, expanding aggregate commitments from $1 billion to $1.25 billion. The facility's termination date has been extended to 19 September 2031. The revised facility, arranged with a syndicate of major international banks, adjusts certain financial definitions and covenants. This provides the healthcare distribution company with greater flexibility in its capital structure. Henry Schein intends to use the enlarged credit facility for working capital and general corporate purposes. These include capital expenditures, share repurchases, refinancing existing debt, and funding potential acquisitions. The agreement includes customary representations, warranties, covenants, and events of default. The company supplies dental, medical, and animal health products to office-based practitioners and healthcare organisations in North America and international markets.
MD Sass Concentrated Value Strategy highlighted Henry Schein as a notable contributor in its second-quarter 2026 investor letter. The healthcare solutions provider saw its shares appreciate 13% during the quarter. The asset management firm believes significant cost reductions combined with accelerating revenue growth should lead to material positive earnings revisions moving into the fourth quarter and 2027. MD Sass met with Henry Schein's new chief executive officer, Fred Lowery, and expects his distribution experience and operational approach to improve efficiencies, margins, and market share. The firm's estimates remain well above consensus over the next several years. Henry Schein closed at $89.52 per share on 28 August 2026, with a market capitalisation of $9.98 billion.
Henry Schein reported second-quarter results that exceeded Wall Street expectations, with revenue of $3.46 billion versus analyst estimates of $3.37 billion and adjusted EPS of $1.27 versus $1.24 expected. The company attributed the performance to accelerating internal sales growth and robust gains in its global dental merchandise segment. CEO Frederick Lowery highlighted success in converting occasional buyers into regular customers and strong market share gains in the US and Canada. The company slightly raised its full-year adjusted EPS guidance to $5.34 at the midpoint. During the earnings call, analysts questioned the sustainability of US dental consumables growth and the timing of value creation benefits. CFO Ronald South indicated most operating income improvements from these initiatives would materialise in the second half of the year.
Henry Schein reported second-quarter sales of $3.5 billion, up 6.7% year-over-year, driven by 4.6% internal local-currency growth and foreign exchange benefits. The healthcare distributor raised its full-year guidance following stronger-than-expected performance. GAAP net income rose to $94 million, or $0.82 per diluted share, from $86 million a year earlier. Non-GAAP earnings reached $1.27 per share, up 15.5% from $1.10 in the prior-year period. Operating margins expanded across all segments. GAAP operating margin increased 27 basis points to 4.94%, whilst non-GAAP operating margin grew 25 basis points to 7.21%. US dental merchandise sales climbed 8.3%, including 6.5% internal growth, with the company reporting market-share gains. Chief Executive Officer Fred Lowery attributed results to operational execution and early benefits from its value-creation programme.